Intervention

Gliclazide

ClinicalTrials.gov intervention label

Clinical trials18

Recruiting0

Common conditions10

Lead sponsors shown14

Clinical trials

18 shown

Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical TrialNCT06085703 · 2024-04-01

Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.NCT06222476 · 2024-02-20

Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid MetabolisersNCT04198948 · 2019-03-04

Study of Sulphonylurea Synergy With IncretinsNCT03705195 · 2018-08-03

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM PatientsNCT03313661 · 2017-10-14

HbA1c Variability in Type II DiabetesNCT02879409 · 2016-11-01

ACTIVE_NOT_RECRUITING

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanNCT02694263 · 2016-07-01

Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to GliclazideNCT02610088 · 2015-11-01

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over StudyNCT02201602 · 2014-08-01

Antidiabetic Effects on Intrahepatic FatNCT03068065 · 2014-05-01

Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.NCT01991197 · 2014-04-01

Safety Evaluation of Adverse Reactions in DiabetesNCT02092597 · 2013-10-01

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During RamadanNCT01758380 · 2013-01-01

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)NCT01709305 · 2012-11-08

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)NCT01590771 · 2012-07-09

Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of MetforminNCT00169624 · 2005-10-01

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 DiabetesNCT00102466 · 2005-01-01

Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 DiabetesNCT00102388 · 2005-01-01

Common conditions

Type 2 Diabetes Mellitus7 Diabetes Mellitus, Type 24 Diabetes3 Coronary and Peripheral Endothelial Dysfunction1 Diabetes Mellitus Type 21 Diabetic Nephropathy Type 21 Mild Cognitive Impairment1 Non-Alcoholic Fatty Liver Disease1 Psoriasis1 Type2 Diabetes1

Leading sponsors

Novartis Pharmaceuticals3 Merck Sharp & Dohme LLC2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2 Charles University, Czech Republic1 Hospices Civils de Lyon1 Khoo Teck Puat Hospital1 Seoul National University Bundang Hospital1 Sherief Abd-Elsalam1 University College Dublin1 University of Dundee1 University of Leicester1 University of Sarajevo1 Weill Cornell Medical College in Qatar1 Yan Bi1

Trial status mix

COMPLETED14

UNKNOWN2

ACTIVE_NOT_RECRUITING1

TERMINATED1

Phase mix

PHASE47

PHASE35

NA4

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.